⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Mary BussM.D.

Medical Oncology · Boston, MA 02215

NPI: 1053382606

Share:

34

🟠 Elevated

Risk Flags

Extreme opioid rate vs specialty peers90th percentile opioid prescribingElevated long-acting opioid rate

Risk indicators are statistical patterns, not allegations. Learn more

298

Total Claims

$20K

Drug Cost

53

Beneficiaries

$379

Cost/Patient

Risk Score Breakdown 34/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid rate vs specialty peers+25
Opioid rate (national percentile)+5
Long-acting opioid rate+4

Score components are additive. Read full methodology

Peer Comparison vs. 3,372 Medical Oncology providers

+599%

Opioid rate vs peers

40.9% vs 5.9% avg

-97%

Cost per patient vs peers

$379 vs $12K avg

+7%

Brand preference vs peers

14.4% vs 13.4% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

🔎 Data Overview

⚠️

Opioid prescribing rate is 599% above the average for Medical Oncology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

40.9%

Opioid Rate

122

Opioid Claims

$6,795

Opioid Cost

40.2%

Long-Acting Rate

This provider's opioid prescribing rate of 40.9% is above the 20% threshold that CMS considers elevated.

Brand vs Generic

86% generic

Brand: 43 claims · $11K

Generic: 255 claims · $8,874

Patient Profile

70

Avg Age

57%

Female

3.42

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About